U.S. market Closed. Opens in 1 hour 4 minutes

SAVA | Cassava Sciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 25.72 - 28.27
52 Week Range 8.79 - 42.20
Beta -0.24
Implied Volatility 450.82%
IV Rank 100.00%
Day's Volume 1,822,007
Average Volume 1,630,745
Shares Outstanding 48,110,500
Market Cap 1,253,278,525
Sector Healthcare
Industry Biotechnology
IPO Date 2000-07-14
Valuation
Profitability
Growth
Health
P/E Ratio -18.88
Forward P/E Ratio -10.99
EPS -1.38
1YR Price Target 84.00
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 29
Country USA
Website SAVA
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.
*Chart delayed
Analyzing fundamentals for SAVA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see SAVA Fundamentals page.

Watching at SAVA technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on SAVA Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙